Lilly, UHG become research bedfellows
Eli Lilly and UnitedHealth Group announced early last month that they are teaming up to conduct a “pragmatic” study of Lilly’s bamlanivimab, a monoclonal antibody developed as a treatment for COVID-19.
Eli Lilly and UnitedHealth Group announced early last month that they are teaming up to conduct a “pragmatic” study of Lilly’s bamlanivimab, a monoclonal antibody developed as a treatment for COVID-19. The FDA’s emergency use authorization of bamlanivimab limits it use to patients who have not been hospitalized.
UnitedHealthcare Medicare Advantage members will be invited to participate. Study volunteers will use a symptom-checker app developed by Optum, which is part of UnitedHealth. If they experience symptoms, they will take a self-
administered test for SARS-Cov-2, the virus that causes COVID-19. An Optum Infusion Pharmacy nurse will oversee at-home infusions of bamlanivimab. Many non-COVID-19 patients getting treated at infusion centers are immunocompromised, so home infusion of this treatment might very well have some safety advantages. The primary outcome measure is hospitalizations in the 28-day period after the drug is infused.
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
